Buy AngioDynamics (Nasdaq: ANGO). Today we add AngioDynamics to our portfolio, following the lead of BlackRock (NYSE: BLK), the largest global investment management corporation (by assets under management) in the world. Normally, when BlackRock owns a stock we aren’t overly impressed—after all, BlackRock literally holds thousands of stocks so an… Read More
Scott Chan moved from China to the U.S. with family at the age of ten. He passed the rigorous entrance exam and attended the merit-based Stuyvesant High School, widely held to be best public school in New York City. He earned undergraduate degrees from New York University followed by an MBA degree from the Zicklin School of Business at Baruch College.
Shortly thereafter Scott partnered with Dr. Stephen Leeb on numerous financial publications. Today, he serves as the lead analyst for Real World Investing and The Complete Investor.
Mr. Chan is an avid baseball fan and enjoys outdoor activities in his spare time. A multicultural person, he reads Chinese and speaks fluent Mandarin and Cantonese Chinese.
Following the lead of two highly successful investing gurus dubbed “oracles” by Wall Street, we have just added Synchrony Financial (NYSE: SYF) to our portfolio. Both the Oracle of Omaha, Warren Buffett, and the Oracle of Boston, Seth Klarman, hold large stakes in the company. Buffett’s Berkshire Hathaway (NYSE: BRK.B)… Read More
Buy Synchrony Financial (NYSE: SYF) Today we are following the lead of two “oracles.” Both the Oracle of Omaha Warren Buffett and the Oracle of Boston Seth Klarman have bet big on Synchrony Financial (NYSE: SYF). Buffett’s Berkshire Hathaway (NYSE: BRK.B) owns 17.5 million shares Klarman’s Baupost Group owns 29.3… Read More
Merger talk between T-Mobile (Nasdaq: TMUS) and Sprint (NYSE: S) is again heating up. While a marriage between the third and fourth largest U.S. national mobile carriers may not be a great thing for consumers, from an investment perspective it looks like it could be a "win-win" situation for both companies. Read More
ViaSat (Nasdaq: VSAT) has completed the Critical Design Review (CDR) for its ViaSat-3 class spacecraft, and is ready to move to the building, integration and testing phase for the first two (of three) satellites to be deployed. The company will once again work with Boeing (NYSE: BA) to build the… Read More
New pick Jazz Pharmaceuticals (Nasdaq: JAZZ) specializes in treating ailments related to sleep disorders and has an expanding portfolio focused on cancers of the blood. The shares are modestly valued by the market, and offer interesting potential upside. Read on for more details. Read More
Sell BYD Company (OTCMKTS: BYDDF). BYD Company (OTCMKTS: BYDDF) has caught fire since a Chinese official revealed that China was considering a timetable for phasing out cars that run on fossil fuels entirely. While we like BYD, the largest electric-car maker in the world, in the long run, in the… Read More
Buy Jazz Pharmaceuticals (Nasdaq: JAZZ) We are adding to our portfolio the top holding in Cadian Capital Management, a hedge fund with about $3 billion in asset under management. Cadian owns 1.39 million shares of Jazz Pharmaceuticals (Nasdaq: JAZZ), making it the largest holding in Cadian’s equity portfolio, with a… Read More